| Similar Articles |
 |
The Motley Fool March 5, 2004 Paul Elliott |
Martha, Martha, Martha She's guilty as charged. What can we all learn from Martha Stewart's misfortune. Don't buy or sell stocks on rumors.  |
The Motley Fool April 27, 2004 Alyce Lomax |
Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux.  |
The Motley Fool September 1, 2004 Bill Mann |
Triumph of Hope Over Reason A frighteningly expensive drug of marginal efficacy begets triple-digit multiples? Bring on the miracles. Standard & Poor's reiterated its "buy" rating of ImClone.  |
BusinessWeek March 8, 2004 Arnst & Ewing |
The Odyssey Of A Cancer Drug How ImClone overcame scandal and FDA objections to get Erbitux to market  |
The Motley Fool July 20, 2006 Brian Lawler |
No Surprises From ImClone ImClone's lead product experienced strong revenue growth in the second quarter. But biotech investing is fraught with risk. Investors, take note.  |
The Motley Fool January 29, 2007 Brian Lawler |
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note.  |
The Motley Fool April 20, 2004 Charly Travers |
Great Googly Moogly, ImClone The biopharmaceutical company's stock is going crazy again.  |
The Motley Fool September 28, 2006 Brian Lawler |
Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.  |
The Motley Fool June 12, 2007 Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label.  |
The Motley Fool September 11, 2008 Brian Lawler |
ImClone and Bristol-Myers' Unfinished Business ImClone rejects Bristol's offer, but likely isn't done dealing with it yet.  |
The Motley Fool February 16, 2010 Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.  |
The Motley Fool August 1, 2007 Brian Lawler |
ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth.  |
The Motley Fool March 24, 2004 Rick Aristotle Munarriz |
Martha Washing Done? The worst may be behind Martha Stewart's media empire. Is the stock a buy?  |
The Motley Fool April 27, 2007 Brian Lawler |
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note.  |
The Motley Fool April 28, 2008 Brian Lawler |
ImClone on the Upswing The pharmaceutical's latest results show continuing improvement.  |
The Motley Fool April 5, 2007 Brian Lawler |
ImClone Steps to the Front ImClone announces a successful clinical trial for the cancer drug Erbitux. Investors, take note.  |
Fast Company September 2004 Linda Tischler |
The Trials of ImClone A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch, it was the turnaround from hell.  |
The Motley Fool October 18, 2004 Charly Travers |
Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers?  |
The Motley Fool June 4, 2008 Brian Lawler |
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares.  |
The Motley Fool April 7, 2011 Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.  |
The Motley Fool January 26, 2009 Brian Orelli |
Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.  |
The Motley Fool March 8, 2004 Dave Marino-Nachison |
Martha Looks Around the Corner Stewart watchers are now guessing at the future of the home-making empire.  |
The Motley Fool September 13, 2007 Brian Lawler |
ImClone Expanding on Erbitux ImClone's turnaround continues with positive results in a cancer study with their lead drug Erbitux.  |
The Motley Fool December 20, 2004 Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped.  |
The Motley Fool August 1, 2008 Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal?  |
The Motley Fool October 2, 2008 Brian Orelli |
Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal?  |
The Motley Fool May 19, 2004 Rick Aristotle Munarriz |
Martha Gets Canned Martha Stewart Living Omnimedia takes a break from its plans for world domination.  |
The Motley Fool May 3, 2004 Rich Smith |
ImClone's Buy-and-Hold Lesson Long-term buy-and-hold investing could have saved Martha more than just jail time.  |
The Motley Fool November 19, 2004 Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer.  |
The Motley Fool July 9, 2008 Brian Lawler |
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.  |
The Motley Fool June 18, 2010 Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday.  |
The Motley Fool February 26, 2011 Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty.  |
The Motley Fool October 30, 2007 Brian Lawler |
ImClone Onward Global sales, and excitement about new label expansions for lead drug Erbitux, lift ImClone's third-quarter financial results.  |
The Motley Fool May 7, 2004 Alyce Lomax |
A Martha Stewart Identity Crisis What's in a name? For Martha Stewart Living, it might be a matter of life-or-death.  |
The Motley Fool July 30, 2010 Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.  |
The Motley Fool July 16, 2007 Brian Lawler |
Slight Setback for ImClone ImClone announces a failed cancer study. Investors, take note.  |
The Motley Fool April 5, 2010 Brian Orelli |
1 Month to Go! Is Dendreon a Buy? Only if you understand the risks.  |
The Motley Fool April 17, 2007 Brian Lawler |
ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note.  |
The Motley Fool January 30, 2004 David Murphy |
Trying Times for Martha What does the Stewart trial mean for her company's bottom line?  |
The Motley Fool September 29, 2006 Brian Lawler |
ImClone Under Siege Board member Carl Icahn moves to take control, and it appears as though shareholders agree.  |
The Motley Fool February 16, 2007 Brian Lawler |
The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc.  |
The Motley Fool July 16, 2004 Brian Gorman |
Martha's Light Sentence Martha Stewart Living Omnimedia investors cheered her light sentence, but the fate of the queen of the domicile probably isn't that important.  |
The Motley Fool December 31, 2010 Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.  |
The Motley Fool December 31, 2007 Brian Lawler |
The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.  |
The Motley Fool November 29, 2011 Brian Orelli |
Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.  |
The Motley Fool September 16, 2004 Seth Jayson |
Martha Cleans Up There's no disguising the fact that this is about repairing a brand in order to sell more magazines, more towels at Kmart, and more books on Amazon.com. But that should be worth something to shareholders.  |
| Knowledge@Wharton |
Bristol-Myers Squibb Illustrates Woes of Ailing Pharmaceutical Industry The once-mighty pharmaceutical industry, for years the nation's most profitable, has begun to show some cracks. But no major U.S. drug maker seems to be facing more problems than Bristol-Myers Squibb.  |
The Motley Fool May 21, 2004 Bob Bobala |
Martha Surges on Perjury A bump in the Martha Stewart case sends her company's stock to the moon.  |
The Motley Fool June 16, 2011 Brian Orelli |
Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA.  |
Chemistry World June 22, 2011 Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe.  |